Smoking during chemotherapy undermines treatment in several ways at once: it changes how quickly your body clears certain drugs, it helps tumor cells resist being killed, it worsens side effects, and it raises the odds of dying from your cancer. A large systematic review found that patients who smoked during cancer treatment had roughly 60% higher mortality risk compared with former or never smokers. The picture is not just about long-term survival statistics, though. Smoking affects day-to-day treatment experience, healing after surgery, the chance of developing an entirely new cancer, and even which drug doses your oncologist should consider.
Your Body Processes Drugs Differently When You Smoke
Cigarette smoke contains thousands of chemicals, and several of them rev up the liver enzymes responsible for breaking down medications. This matters because many chemotherapy drugs have narrow therapeutic windows, meaning there is a relatively small gap between a dose that works and a dose that is too low to do much. When your liver metabolizes a drug faster than expected, the drug spends less time in your bloodstream at effective concentrations, and tumors get less exposure to it.
One well-studied example is erlotinib, a targeted therapy used in lung cancer. Research found that current smokers had blood levels of erlotinib roughly half those of former smokers, along with a 23.5% increase in how quickly their bodies cleared the drug. That is not a subtle difference. It can be the gap between a drug that shrinks a tumor and one that barely touches it. Erlotinib is not the only drug affected; the same enzyme-induction pathway influences the metabolism of several other agents used across cancer types. Some oncologists adjust doses upward for patients who smoke, but this is not standard practice everywhere, and higher doses can bring their own toxicity risks.
Nicotine Helps Cancer Cells Survive
Beyond altering drug levels, nicotine itself actively interferes with what chemotherapy is trying to do. The whole point of most chemo agents is to trigger cancer cells to self-destruct through a process called apoptosis. Nicotine flips molecular switches inside those cells that block that self-destruction signal. Lab studies on lung cancer cells showed that nicotine prevented chemotherapy-induced cell death, improved cancer cell survival, and modestly increased DNA production in those cells. The effect was traced to specific signaling pathways that, when activated by nicotine, ramp up the cell’s anti-death defenses.
This finding has been replicated in other tissue types as well. In nasal epithelial cancer cells treated with a standard combination of cisplatin and etoposide, nicotine partially blocked the apoptosis that the drug combination was supposed to cause. When researchers shut down those same signaling pathways, nicotine’s protective effect on the cancer cells was reduced. The implication is uncomfortable but clear: the nicotine you inhale is not just a bystander during treatment. It is actively working against your chemotherapy at the cellular level.
This also has implications for nicotine replacement therapies like patches or gum, which some patients use to quit smoking during treatment. The concentrations of nicotine from these products are lower and steadier than those from cigarettes, and they eliminate the thousands of other harmful chemicals in smoke. Still, the question of whether even therapeutic nicotine blunts chemo effectiveness to some degree remains an area of active research. Most oncologists consider nicotine replacement far safer than continued smoking, but it is worth discussing with your care team.
Reduced Oxygen Delivery to Tumors
A separate mechanism comes into play when chemotherapy is combined with radiation, which is common in cancers of the head and neck, lung, and cervix. Radiation therapy works best when tumor cells are well-oxygenated, because oxygen helps lock in the DNA damage that radiation inflicts. Smoking floods your blood with carbon monoxide, which binds to hemoglobin far more tightly than oxygen does. The result is that less oxygen reaches the tumor.
A prospective study of head and neck cancer patients treated with radiotherapy found that the poorer tumor control seen in smokers could be explained by elevated carboxyhemoglobin levels, meaning a reduced oxygen supply to the tumors. This is not a theoretical concern; it directly affects how well the radiation component of treatment performs, and since many chemo regimens are given alongside radiation as a combined approach, smoking can diminish both treatments at once.
Higher Symptom Burden During and After Treatment
Even if outcomes like survival and recurrence feel abstract when you are in the middle of treatment, the day-to-day experience of chemotherapy is something patients feel acutely. Smokers report a meaningfully worse time. A study tracking cancer patients through treatment and into follow-up found that smokers had a significantly higher total symptom burden during treatment compared with nonsmokers. At the six-month follow-up mark, smokers still reported worse symptoms. Patients who had quit before treatment started reported symptom levels similar to those of people who had never smoked.
The types of symptoms that tend to be worse include fatigue, pain, shortness of breath, and appetite problems. Some of these overlap with side effects that smoking causes independently of cancer, which makes it hard for patients to tell what is chemo-related and what is tobacco-related. That blurring can lead to underreporting of symptoms to the care team, which means problems that could be managed go unaddressed.
Smoking also affects tolerance of treatment in broader terms. Cancer patients who continue to smoke are more likely to experience treatment interruptions or dose reductions because of complications, and these disruptions can reduce the overall effectiveness of their regimens.
What the Survival Data Actually Shows
The mortality numbers are stark. A systematic review and meta-analysis that pooled results across cancer types and treatment modalities found that active smoking during treatment was associated with a hazard ratio of 1.61 for overall survival, meaning smokers had about 61% higher risk of death compared with former or never smokers. Cancer-specific mortality was also worse, with a hazard ratio of 1.25. These figures held after accounting for the type of cancer and the treatment approach used.
For progression-free survival during chemotherapy specifically, the picture is a bit muddier. A separate meta-analysis of six studies including about 1,500 patients found that smoking during chemotherapy was not significantly associated with progression-free survival, though the confidence intervals were wide enough that a real effect could be hiding in the noise. The overall survival disadvantage, however, was consistent and statistically robust. One way to read this: smoking may not always make your tumor grow faster in the short term, but it increases your odds of dying from your disease or its complications over the longer haul.
The Risk of a Second Cancer
Surviving one cancer does not make you immune to developing another. Cancer survivors who continue to smoke face a substantially elevated risk of what oncologists call a second primary cancer, a new and unrelated malignancy. A study of cancer survivors found that current smokers had 76% higher risk of developing any second primary cancer compared with never smokers. For cancers specifically linked to tobacco, the risk was even more dramatic: current smokers had 136% higher risk of a smoking-related second cancer. Survivors who had recently quit had measurably lower risk than those who kept smoking.
A meta-analysis examining this question found that current smokers had roughly 2.8 times the risk of a smoking-related second primary cancer compared with never smokers, while former smokers had about 1.4 times the risk. The pattern is dose-dependent and durable: the longer you smoke and the more you smoke, the higher the risk climbs. Quitting does not erase past exposure, but it bends the risk curve downward.
This risk is distinct from recurrence of the original cancer. A recurrence means the first cancer has come back; a second primary means an entirely new cancer has formed. Smoking raises the risk of both, but the second-primary risk is sometimes overlooked in conversations with patients, especially those whose original cancer was not tobacco-related. If you had breast cancer, for example, you might not think of smoking as a factor in your ongoing cancer risk, but the data says otherwise.
A Paradox With Certain Side Effects
Not every finding about smoking and chemotherapy points in the same direction, and one result catches people off guard. A study of patients receiving gemcitabine, a chemotherapy drug commonly used in pancreatic and other cancers, found that patients with a history of smoking were significantly less likely to develop severe neutropenia, a dangerous drop in white blood cells. Among non-smokers, about 56% experienced severe neutropenia, compared with roughly 24% of patients with a smoking history. After adjusting for other factors, a history of smoking remained an independent predictor of lower neutropenia risk.
This does not mean smoking protects you from side effects in any meaningful sense. The likely explanation circles back to the same enzyme-induction phenomenon described earlier: smokers metabolize gemcitabine faster, so the drug clears from their system more quickly and does less damage to their bone marrow. The flipside of that coin is that the drug may also be spending less time fighting the tumor. A side effect that appears milder because the drug is being cleared too fast is not a benefit. It is a sign that treatment is being diluted.
Surgical Healing and Combined Treatment Plans
Many cancer treatment plans involve surgery at some point, whether before, during, or after chemotherapy. Smoking is a well-known risk factor for surgical complications in any context, and cancer surgery is no exception. An analysis of breast surgery patients found that smoking was an independent predictor of wound complications in multivariable analysis, alongside factors like diabetes and obesity. Interestingly, neoadjuvant chemotherapy (chemo given before surgery) was not itself significantly associated with wound complications, but smoking was, regardless of whether chemo had been given beforehand.
Wound healing depends heavily on adequate blood flow and oxygen delivery to tissues, both of which are impaired by smoking. Poor wound healing can delay the next phase of treatment. If you need adjuvant chemotherapy or radiation after surgery but your surgical wound is not healing, those treatments may have to wait. Each delay creates a window where microscopic residual disease has time to grow.
Quitting at Diagnosis Makes a Measurable Difference
If the picture so far sounds bleak for patients who smoke, there is a genuinely encouraging counterpoint: quitting at the time of diagnosis leads to measurably better outcomes. A comprehensive meta-analysis of 25 cohort studies involving over 17,500 lung cancer patients found that quitting smoking at diagnosis was associated with a 26% reduction in mortality risk. The benefit was seen in both non-small cell and small cell lung cancer, with an even more pronounced effect among patients with earlier-stage disease, where quitting was associated with a 36% reduction in mortality.
Formal cessation programs appear to amplify the benefit further. In that same analysis, patients who received active smoking cessation interventions had substantially better survival than those who quit without structured support. A separate meta-analysis of randomized controlled trials found that smoking cessation interventions for cancer patients increased quit rates by about 36% overall compared with control groups. Programs with at least five points of contact (phone calls, counseling sessions, or follow-ups) tended to perform better.
The “teachable moment” theory suggests that a cancer diagnosis creates a unique window of motivation. Patients are often more receptive to quitting at this point than at any other time in their lives. Yet the research on how consistently oncology teams actually address smoking tells a less flattering story.
Gaps in How Smoking Gets Addressed During Cancer Care
You might assume that every oncologist asks about smoking and offers cessation support, but documentation suggests otherwise. A study examining radiotherapy patients found major gaps depending on cancer site. Lung and head-and-neck cancer patients had their smoking history recorded at consultation around 96-97% of the time, which makes sense given the direct link between tobacco and those cancers. But among prostate cancer patients, only about 65% had their smoking history documented. Cessation discussions were documented for roughly half of head-and-neck and lung cancer patients but for only about 14% of breast and prostate cancer patients.
The disparity reflects an understandable but damaging bias: if your cancer is not commonly associated with smoking, your care team may be less likely to bring it up. But as the evidence above shows, smoking affects treatment outcomes regardless of whether tobacco caused the original cancer. A breast cancer patient who smokes faces worse symptoms, slower wound healing, altered drug metabolism, and higher risk of a second cancer, just like a lung cancer patient who smokes. The conversation should happen for everyone.
If your oncologist has not raised the topic, it is worth bringing it up yourself. Asking about cessation support, nicotine replacement options, and whether your smoking status affects any dosing decisions puts the issue on the table. Many cancer centers now have dedicated tobacco treatment programs embedded in their oncology services, though access varies widely.
What About E-Cigarettes and Vaping
A question that comes up increasingly is whether switching to e-cigarettes during chemotherapy is a reasonable compromise. The honest answer is that the evidence base is still thin. E-cigarettes deliver nicotine without the combustion byproducts that cause most of smoking’s cardiovascular and pulmonary harm. That means some of the mechanisms described above, like carbon monoxide reducing oxygen delivery to tumors, would largely be eliminated. However, nicotine’s direct effect on cancer cell survival pathways would remain, since vaping still delivers nicotine.
No large clinical trials have yet compared outcomes of cancer patients who switch to vaping versus those who quit nicotine entirely. Most oncologists would prefer complete cessation of all nicotine products, but recognize that some patients find it impossible to quit nicotine cold during an already overwhelming time. The pragmatic view held by many clinicians is that if the alternative is continued cigarette smoking, switching to nicotine replacement therapy or even e-cigarettes is likely the lesser harm, though truly quitting remains the goal.
The Financial Dimension
Cancer treatment is expensive under any circumstances, but smoking can drive costs even higher. Complications, treatment delays, additional hospitalizations for infections or wound problems, and longer recovery times all add to the bill. Research from a national cancer institute found that chemotherapy was the costliest component of care for patients with advanced non-small cell lung cancer, with average annual medical care costs reaching tens of thousands of dollars for stage III disease and substantially more for stage IV. When smoking-related complications extend treatment timelines or require additional interventions, these costs escalate further.
For patients dealing with the financial toxicity of cancer care, which is itself a recognized problem associated with worse adherence and outcomes, the additional costs driven by continued smoking represent something within their control. Cessation support, where available, is typically covered by insurance and is among the most cost-effective interventions in all of medicine.